Yazici Hilmi, Esmer Ahmet Cem, Altunsu Sena, Dağdemir Barış, Yildiz Aysenur, Yegen Sevket Cumhur
General Surgery Department, Marmara University Pendik Research and Training Hospital, Istanbul, Turkey.
Cancer Control. 2025 Jan-Dec;32:10732748251376793. doi: 10.1177/10732748251376793. Epub 2025 Sep 4.
IntroductionThis retrospective study compares the outcomes of right hemicolectomy (RHC) and extended right hemicolectomy (ERHC) in patients with hepatic flexure and proximal transverse colon tumors.MethodsData from 85 patients who underwent surgery for colonic adenocarcinoma between January 2015 and December 2023 were analyzed retrospectively. Patients who had hepatic flexure and proximal transverse colon tumors were included in the analysis. Patients were divided into two groups: RHC and ERHC. The primary endpoints were overall survival (OS) and disease-free survival (DFS), with secondary outcomes including postoperative complications and pathological data.ResultsThe RHC group comprised 46 patients, while the EHRC group had 39 patients. The study found no significant difference in 5-year OS (77% RHC vs 69% ERHC, = 0.135) or 5-year DFS (87% RHC vs 81% ERHC, = 0.388) between the two groups. Although the ERHC group had a higher number of harvested lymph nodes (27 vs 22, = 0.022), this did not correlate with improved survival outcomes. Tumor localization was identified as a significant factor influencing OS, with hepatic flexure tumors showing better survival compared to proximal transverse colon tumors. No significant differences were observed between the groups regarding postoperative complications.ConclusionOur study suggests that while ERHC leads to a higher lymph node yield, it does not significantly improve survival outcomes compared to RHC in patients with hepatic flexure and proximal transverse colon tumors. Further research is needed to optimize surgical strategies and improve patient outcomes.
引言
本回顾性研究比较了肝曲和横结肠近端肿瘤患者行右半结肠切除术(RHC)和扩大右半结肠切除术(ERHC)的疗效。
方法
回顾性分析2015年1月至2023年12月期间85例行结肠腺癌手术患者的数据。纳入肝曲和横结肠近端肿瘤患者进行分析。患者分为两组:RHC组和ERHC组。主要终点为总生存期(OS)和无病生存期(DFS),次要结局包括术后并发症和病理数据。
结果
RHC组46例患者,ERHC组39例患者。研究发现两组间5年总生存期(RHC组77% vs ERHC组69%,P = 0.135)或5年无病生存期(RHC组87% vs ERHC组81%,P = 0.388)无显著差异。尽管ERHC组切除的淋巴结数量更多(27个 vs 22个,P = 0.022),但这与生存结局改善无关。肿瘤定位被确定为影响总生存期的重要因素,肝曲肿瘤的生存率高于横结肠近端肿瘤。两组术后并发症无显著差异。
结论
我们的研究表明,对于肝曲和横结肠近端肿瘤患者,虽然ERHC可获得更高的淋巴结收获量,但与RHC相比,并未显著改善生存结局。需要进一步研究以优化手术策略并改善患者结局。